Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 22 June 2016 | By Zachary Brennan
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on Wednesday began exchanging more information on the best practices of involving patients in the development, evaluation and post-authorization tracking of medicines.
The EMA/FDA teleconference, also known by EMA as a "cluster," on patient engagement seeks to increase the exchange of information on engaging with and involving patients and their organizations within the regulators’ work, as well as exchanging more information on internal policies, guidance documents and regulations, particularly for high-profile products/topics of mutual interest.
The two drug regulators also hold regular teleconferences on:
Areas of future discussion on patient engagement will also include the processes for selecting and preparing patients to take part in the agencies’ activities, how to ensure that patients are independent and representative, and how to report on the impact of patient involvement, EMA said.
“Our aim as regulators is to make sure that patients have access to safe and effective medicines that improve their lives. It is important to engage to be able to fully understand their needs and priorities and make their voice heard along a medicine’s lifecycle,” Guido Rasi, EMA executive director, added. “Many of the challenges and benefits of working with patients are similar for both regulators.”
The new cluster is expected to meet three to four times per year via hour-and-a-half long teleconferences, and will involve officials from FDA’s Office of International Programs, Office of Health and Constituent Affairs, as well as from the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. The clusters will be chaired jointly by FDA and EMA.
Terms of reference for the EMA/ FDA cluster on patient engagement
EMA and FDA reinforce collaboration on patient engagement
Tags: EMA cluster, patient engagement, drug regulators working with patients
Regulatory Focus newsletters
All the biggest regulatory news and happenings.